Introduction {#Sec1}
============

Fulminant type 1 diabetes (FT1D) is a subtype of type 1 diabetes (T1D); it is characterized by the abrupt onset of insulin-deficient hyperglycemia and ketoacidosis within a few days \[[@CR1]\].

The specific etiology and pathogenesis of FT1D are unclear and may be related to genetic predisposition, autoimmunity, viral infection, and pregnancy.

Viral infection is strongly associated with fulminant diabetes, as reported previously, and can be associated with frequent flu-like symptoms along with a seasonal variation in time of onset. A viral infection is suggested to play a role in rapid β cell destruction.

Epidemiological studies have indicated an association between enteroviruses (EVs) and T1D \[[@CR2]\]. Certain class II human leukocyte antigens (HLA) are known to increase susceptibility to FT1D during pregnancy \[[@CR3]\]. However, the association between FT1D in pregnancy and specific viral infections has not been reported.

We report the case of a patient who developed FT1D in pregnancy accompanied by Coxsackievirus B1 infection.

Case presentation {#Sec2}
=================

Our patient was a 31-year-old Japanese woman, gravida 1, para 1. She had no remarkable medical history, and there were no abnormalities during her medical examination. Her father and uncle had type 2 diabetes requiring insulin therapy. However, her sister did not have diabetes. The weight gain during her first 3 months of pregnancy was 1.1 kg. A regular examination at 29 weeks and 5 days was normal; her blood glucose level was 73 mg/dL, with negative levels of urinary glucose, and 3+ urinary ketone bodies.

At 30 weeks and 6 days, she was admitted with marked fatigue and dyspnea. However, she did not present with fever, headache, costochondritis, pharyngitis, diarrhea, maculopapular non-pruritic rash, nausea, or flu-like symptoms such as a sore throat, cough, or rhinorrhea.

On admission, she was alert. A physical examination revealed the following: temperature (T), 36.7 °C; pulse rate (P), 94 beats per minute (bpm); respiratory rate (R), 18/minute; and blood pressure (BP), 121/65 mmHg; fetal bradycardia was also observed, for which emergency cesarean section was performed, but the child was stillborn. The laboratory findings revealed diabetic ketoacidosis (DKA), with random sample glucose of 427 mg/dL, C-peptide reactivity (CPR) of 0.04 ng/mL, arterial pH of 6.91, bicarbonate of 6.7 mEq/L, and 3+ urinary ketone bodies. Despite the presence of DKA, the glycated hemoglobin (HbA1c) value was within the normal range (6.2%), and urinary CPR was extremely low at 0.5 μg/day. In addition, the serum elastase-1 and lipase levels were increased to 1939 (\< 300) ng/dL and 119 (11--53) U/L, respectively. Antibody level against glutamic acid decarboxylase was 1.2 (\< 1.5) U/mL. Neither anti-insulin nor anti-insulinoma-associated antigen-2 antibodies were detected. HLA II haplotypes showed *DR8,12/DQ7,4*. These results were indicative of a FT1D diagnosis (Table [1](#Tab1){ref-type="table"}).Table 1Laboratory data on admissionHematologyABGA (O~2~ 5 L/m)WBC14,400 /μlCRP6.4 mg/dlpH6.91neu.74%Amylase139 IU/LpCO~2~33.7 mmHglym.22%Elastase11939 ng/dlPO~2~184 mmHgmon.3%Lipase119 U/LHCO~3~^−^6.5 mmol/Leosino.1%Na129 mEq/lBE−26.1 mmol/LRBC468 × 10^4^ /μlK6.7 mEq/lHb13.5 g/dlCl95 mEq/lUrine analysisHt40.7%Glu427 mg/dlpH5.0Plt47.8 × 10^4^ /μlHbA1c6.2%Protein(2+)Serum C-peptide0.04 ng/mlGlucose(4+)ChemistryTSH2.14 μIU/mlBlood(1+)AST14 IU/LF-T41.03 ng/mlKetone(4+)ALT12 IU/LUrine C-peptide0.5 μg/dayγ-GTP12 IU/LT-Bil0.5 mg/dlCoagulationAutoantibodiesALP328 IU/lPT12.3 secGAD Ab\< 5.0 U/mlTP9 mg/dlAPTT30.9 secIA-2 Ab(−)Alb4.2 g/dlFDP8.47 μg/mlInsulin Ab\< 0.4 U/mlCK29 IU/lD-dimer5.48 μg/mlCRE0.87 mg/dlHLA haplotypeBUN22 mg/dlDR8, DR12, DQ7, DQ4*Ab* antibody, *ABGA* arterial blood gas analysis, *Alb* albumin**,** *ALP* alkaline phosphatase, *ALT* alanine aminotransferase, *APTT* activated partial thromboplastin time, *AST* aspartate aminotransferase, *BE* base excess, *BUN* blood urea nitrogen, *CK* creatine kinase, *CRE* creatinine, *CRP* C-reactive protein, *eosino*. eosinophils, *FDP* fibrin degradation product, *F-T4* free thyroxine, *GAD* glutamic acid decarboxylase, *γ-GTP* gamma-glutamyl transpeptidase, *GLU* glucose, *Hb* hemoglobin, *HbA1c* glycated hemoglobin, *HCO*~*3*~^−^ bicarbonate, *HLA* human leukocyte antigens~,~ *Ht* hematocrit, *lym*. lymphocytes, *mon*. monocytes, *neu*. neutrophils, *pCO*~*2*~ partial pressure of carbon dioxide, *pO*~*2*~ partial pressure of oxygen, *Plt* platelets, *PT* prothrombin time, *RBC* red blood cells, *T-Bil* total bilirubin, *TP* total protein, *TSH* thyroid-stimulating hormone, *WBC* white blood cells

She was diagnosed as having DKA due to FT1D. She was simultaneously treated with fluid replacement and continuous insulin infusion to maintain vital signs, plasma glucose, and electrolyte levels. On day 2, ketonuria, electrolytes, and vital signs had normalized. On day 3, the continuous infusion of insulin was withdrawn, and daily multiple insulin injections were administered with blood glucose monitoring. On day 24, she continued to undergo treatment with multiple daily insulin injection therapy with insulin aspart (25 U/day) and insulin degludec (12 U/day).

Paired serum antiviral antibody test {#Sec3}
------------------------------------

To investigate the association between viral infection and FT1D, we performed serological testing for several viruses such as parainfluenza virus 1--3, Coxsackievirus A2--7, 9, 10, 16, B1--6, cytomegalovirus (CMV), Epstein--Barr virus (EBV), and human herpes virus (HHV) 6 at day 3, day 17, and day 38 (Table [2](#Tab2){ref-type="table"}). A Coxsackievirus B1 antibody titer was significantly elevated from 1:32 to 1:256 (eightfold increase), whereas the other antibodies were not altered.Table 2Viral antibodiesDay 3Day 17Day 38Day 3Day 17Parainfluenza1\< 10\< 10Coxsackie B3\< 4\< 4Parainfluenza2\< 10\< 10Coxsackie B4\< 4\< 4Parainfluenza3160160Coxsackie B5\< 4\< 4Coxsackie A2\< 4\< 4Coxsackie B6\< 4\< 4Coxsackie A388CMV IgM0.490.79Coxsackie A41616CMV IgG\< 2\< 2Coxsackie A5\< 4\< 4EBV anti-VCA IgM00.1Coxsackie A6\< 4\< 4EBV anti-VCA IgG2.22.6Coxsackie A784EBV anti-EBNA IgG3.13.3Coxsackie A948HHV-6 IgM\< 10\< 10Coxsackie A10\< 4\< 4HHV-6 IgG160160Coxsackie A16\< 4\< 16HHV-7 IgM\< 10\< 10Coxsackie B13264256HHV-7 IgG4040Coxsackie B2\< 4\< 4*CMV* cytomegalovirus, *EBNA* Epstein--Barr virus nuclear antigen, *EBV* Epstein--Barr virus, *HHV* human herpes virus, *VCA* viral capsid antigen

Discussion {#Sec4}
==========

FT1D is a special type of T1D that was first proposed by the Japanese scholar, Imagawa, in 2000 \[[@CR1]\]. FT1D is characterized by rapid onset of DKA within a short time period, with normal to near-normal HbA1c levels at onset and complete β cell destruction \[[@CR4]\]. A nationwide survey of FT1D in Japan revealed that it accounts for approximately 20% of cases of T1D \[[@CR5]\]. The specific etiology and pathogenesis of FT1D are unclear and may be related to genetic predisposition, autoimmunity, viral infection, and pregnancy.

It is well known that the immunological milieu is significantly changed during pregnancy. However, the issue of whether the clinical and immunogenetic characteristics are different between the cases associated with and without pregnancy remains to be determined.

Although multiple genes have been implicated, HLA class II genes, especially the HLA-DR and DQ genes, are the most important. HLA class II genotypes *DRB1\*04:05- DQB1\*04:01* strongly confer susceptibility to the development of FT1D \[[@CR6]\]. In contrast, the frequency of *DRB1\*09:01-DQB1\*03:03* tended to be higher in pregnant women with FT1D than in non-pregnant patients with FT1D \[[@CR6]\]. The involvement of HLA class II haplotypes is suggested to vary depending on the presence or absence of pregnancy. In our pregnant patient, the HLA class II haplotypes were *DR8,12/DQ7,4*. To the best of our knowledge, these haplotypes have not been reported as conferring susceptibility to FT1D.

Viral infection is strongly associated with fulminant diabetes, as reported previously, and is evidenced by frequent flu-like symptoms, and it possibly has a seasonal variation in time of onset. Coxsackie B is a group of six types of EVs belonging to the *Picornaviridae* family. Coxsackie B viruses have a tropism for muscle cells and are most common in children but may occur in adults. Clinical manifestations include fever, aseptic meningitis, costochondritis, pharyngitis, myocarditis, diarrhea, and maculopapular non-pruritic rash \[[@CR7]\].

Epidemiological studies have indicated an association between EVs and T1D. These viruses have a strong tropism for insulin-producing β cells; the destruction of these cells leads to T1D \[[@CR8]\]. The exact mechanisms by which EVs could cause T1D are not known, but direct infection of β cells and virus-induced inflammation may play a role. Some studies have narrowed down the epidemiological association to a subset of EVs: group B Coxsackieviruses \[[@CR9]\].

Recent studies have reported a variety of viral infections, including Coxsackievirus B1, B3, B4, A4, A5, A6, CMV, EBV, HHV6, 7, mumps, and parvovirus B19 to be involved in the development of FT1D \[[@CR10]--[@CR12]\]. However, the association between FT1D in pregnancy and certain viral infections has not been reported. Because HLA class II haplotypes with pregnancy and without pregnancy were different, we think it is possible that a different virus causes FT1D. However, our pregnant patient developed a Coxsackievirus B1 infection that manifested as fatigue and was involved in the development of FT1D.

Therefore, this case suggests that Coxsackievirus B infection is associated with FT1D with pregnancy and without pregnancy. DKA is a medical emergency during pregnancy and has high rates of fetal mortality. A prophylactic measure should be available to avoid the development of FT1D in pregnancy. Recent studies have narrowed down the epidemiological association to a subset of EVs: group B Coxsackieviruses; clinical development of a vaccine against T1D-associated EV types has been started \[[@CR9]\]. A Coxsackievirus B vaccine may be protective against the development of FT1D in pregnancy.

Conclusion {#Sec5}
==========

We should assess pregnant women with symptoms of both fatigue and acute hyperglycemia for the presence of DKA, even if they are alert when presenting to the hospital. This case highlights that FT1D in pregnancy may be associated with Coxsackievirus B1 infection.
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